louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05838209: Effect of Ozone Oil After Non-surgical Periodontal Treatment
Official title: Effect of Ozone Oil After Non-surgical Periodontal Treatment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Periodontal Diseases
Keywords: Periodontitis, Periodontal treatment, diabetes
Lead sponsor: Universidade Federal Fluminense
Sponsor class: OTHER
First posted: 2023-05-01
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a prospective clinical randomized controlled, split mouth designed, doble blinded study.
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to evaluate the use of ozone oil as an adjunctive of non-surgical periodontal treatment (NSPT) on diabetics type 2 patients (DM2) compared to control group with chronic periodontal disease.

The principal question is to evaluate if the ozone oil could improve periodontal clinical parameters.

Thirty-two sites of 16 diabetics type 2 patients (DM2) with moderate to advanced periodontal disease containing two sites with periodontal pocket depth (PPD) of \> 5 mm were selected.

The treatment was distributed in 2 groups in the split mouth design: Control- scaling and root planing + saline solution (control) and Test - scaling and root planning + ozone oil


Eligibility criteria: Inclusion Criteria:

* Periodontitis
* Systemic type 2 diabetes

Exclusion Criteria:

* Hypersensitivity to ozone oil
* Osteoporosis types I and II
* Alcoholism
* Immunosuppressio
* Pregnant and lactating
* Physical/emotional stress drugs
* Use of antibiotics, anti-inflammatories and hormone
* Oral candidiasis
* Received periodontal treatment in the last six months prior to the procedure

Primary outcomes:
measure: Plaque Index
timeFrame: baseline
measure: Gingival Index
timeFrame: baseline
measure: Probing Depth
timeFrame: baseline
measure: clinical attachment level
timeFrame: baseline
Secondary outcomes:
measure: Plaque Index
timeFrame: 3 months
measure: Gingival Index
timeFrame: 3 months
measure: Probing Depth
timeFrame: 3 months
measure: clinical attachment levels
timeFrame: 3 months
Other outcomes:
Locations:
city: Nova Friburgo
country: Brazil
facility: Gabriela Alessandra da Cruz Galhardo Camargo
state: RJ
Study officials:
References:
citation: Mauri-Obradors E, Merlos A, Estrugo-Devesa A, Jane-Salas E, Lopez-Lopez J, Vinas M. Benefits of non-surgical periodontal treatment in patients with type 2 diabetes mellitus and chronic periodontitis: A randomized controlled trial. J Clin Periodontol. 2018 Mar;45(3):345-353. doi: 10.1111/jcpe.12858. Epub 2018 Jan 19.
Clinical trial NCT00080509: Effectiveness of KOS-862 in the Treatment of Lung Cancer
Official title: A Phase 2 Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Lung Cancer
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2004-04-07
Enrollment: 85
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior platinum-containing chemotherapy regimen.

Detailed description: To determine the antitumor activity, based on the confirmed objective response rate, of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer (NSCLC) whose disease has progressed following initial chemotherapy for advanced or metastatic disease.

Eligibility criteria: Inclusion Criteria:

* At least 18 years of age
* Measurable disease
* One previous treatment of a platinum based drug such as cisplatin or carboplatin
* At least 3 weeks since last surgery/radiation/chemotherapy

Exclusion Criteria:

* Brain metastases
* Changes in the rhythm of your heart that are considered significant as determined by an ECG tracing

Primary outcomes:
measure: NSCLC
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03351309: Telephone Cognitive Behavioral Therapy for Veterans Undergoing Surgery
Official title: Telephone Cognitive Behavioral Therapy for Veterans Undergoing Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Persistent Post-surgical Pain
Veterans
Lead sponsor: Iowa City Veterans Affairs Medical Center
Sponsor class: FED
Collaborators: name: US Department of Veterans Affairs
First posted: 2017-11-22
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study team propose to investigate the feasibility and pilot a Telephone Cognitive Behavioral Therapy intervention for those identified to be at risk for chronic pain following surgery.


Eligibility criteria: Inclusion Criteria:

1) \>18 years of age, 2) scheduled for hernia repair, breast surgery, amputation, thoracotomy, cholecystectomy, cardiac surgery, splenectomy, orthopedic, urological or vascular surgery, 3) Rural dwelling

Exclusion Criteria:

1) language or cognitive barriers preventing completion of questionnaires, 2) severe psychiatric disorder: bipolar or psychotic disorder, 3) significant surgical complications.

Primary outcomes:
measure: Pain Severity
timeFrame: 3 months post-surgery
Secondary outcomes:
measure: Qualitative analysis of feasibility data
timeFrame: Between 1-2 weeks post-TCBT
measure: Pain severity - continuous
timeFrame: 3 months post-surgery
measure: Pain-related functioning
timeFrame: 3 months post-surgery
measure: Opioid and other analgesic use
timeFrame: 3 months post-surgery
measure: Depression
timeFrame: 3 months post-surgery
measure: Anxiety
timeFrame: 3 months post-surgery
measure: Health-related quality of life: SF-36
timeFrame: 3 months post-surgery
measure: Patient satisfaction with outcomes
timeFrame: 3 months post-surgery
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: Iowa City VA Medical Center
state: Iowa
Study officials:
affiliation: University of Iowa
name: Katherine Hadlandsmyth, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04403009: The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19
Official title: The Clinical Difference Between the Nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the Fatal Cases With Severe COVID-19
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronavirus Disease 2019
Character of the Severe Patients
Lead sponsor: The First Affiliated Hospital of Guangzhou Medical University
Sponsor class: OTHER
First posted: 2020-05-27
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The patients with Coronavirus Disease 2019

Brief summary: To investigate the difference of the difference between the nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the fatal Patients .The cross sectional study was undertaken to compare the clinical information (laboratory and radiologic characteristics)of nonfatal participants and fatal cases. The investigators wish figure out the clinical character of the fatal participants. The result may help the physician to find the fatal patients with COVID-19 more easily. The fatal patients with COVID-19 could be treated early.


Eligibility criteria: Inclusion Criteria:

* The patients with Coronavirus Disease 2019
* Positive result on real-time reverse-transcriptase-polymerase-chain-reaction
* Positive result on chest computed tomography

Exclusion Criteria:

* No

Primary outcomes:
measure: Lymphocyte cell
timeFrame: 2 month
measure: d-dimer
timeFrame: 2 month
measure: PLT
timeFrame: 2 month
measure: CRP
timeFrame: 2 month
measure: LDH
timeFrame: 2 month
measure: CK
timeFrame: 2 month
measure: PT
timeFrame: 2 month
measure: ALT
timeFrame: 2 month
measure: AST
timeFrame: 2 month
measure: NK cell
timeFrame: 2 month
measure: PCT
timeFrame: 2 month
measure: IL-6
timeFrame: 2 month
Secondary outcomes:
measure: the clinical difference of radiologic characteristics between the fatal patients with COVID -19 and the non fatal cases
timeFrame: 2 months
Other outcomes:
measure: SPO2
timeFrame: 2 month
Locations:
city: Guanzhou
country: China
facility: The First Affiliated Hospital of Guangzhou Medical University
state: Guangdong
city: Wuhan
country: China
facility: Hankou Hospital
state: Hubei
Study officials:
affiliation: First Afiliated hospital of Guangzhou medical university
name: jianheng zhang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04596709: Investigation of Blood Glucose and Insulin Response After Intake of Vitalose
Official title: Investigation of Blood Glucose and Insulin Response After Intake of Vitalose and Isomaltulose in Comparison to Sucrose and Glucose
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Adults
Lead sponsor: Beneo-Institute
Sponsor class: INDUSTRY
Collaborators: name: BioTeSys GmbH
First posted: 2020-10-22
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The aim of this study is to assess the postprandial glucose and insulin response of Vitalose.


Eligibility criteria: Inclusion Criteria:

* healthy adults
* Age 18-50 years
* BMI ≥18.5 and ≤30.0 kg/m²

Exclusion Criteria:

* acute or chronic disease
* food allergy or intolerance
* intake of medications which affect glucose tolerance

Primary outcomes:
measure: 2h iAUC for pp glucose response
timeFrame: Baseline, 15, 30, 45, 60, 90, 120 minutes
measure: 2h iAUC for pp insulin response
timeFrame: Baseline, 15, 30, 45, 60, 90, 120 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Esslingen
country: Germany
facility: BioTeSys GmbH
Study officials:
affiliation: BioTeSys GmbH
name: Daniel Menzel, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04266509: Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600
Official title: PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF REPEAT-DOSE RIFAMPIN ON THE PHARMACOKINETICS OF PF-06651600 IN HEALTHY PARTICIPANTS
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: PF-06651600
Rifampin
Drug-drug interaction study
Pharmacokinetics
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2020-02-12
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: BASIC_SCIENCE

Brief summary: Study to Evaluate the Effect of Repeat-Dose Rifampin on the pharmacokinetics (PK) of PF-06651600.


Eligibility criteria: Inclusion Criteria:

* Male and/or female participants who are healthy as determined by medical evaluation including medical history, full physical examination which includes BP and pulse rate measurements, clinical laboratory tests, and 12-lead ECG.
* BMI of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb).

Exclusion Criteria:

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, dermatological or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
* Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
* Systemic therapy with any of the medications that are moderate or strong CYP3A4 and/or CYP2C19 inhibitors within 28 days or 5 half-lives (whichever is longer) or moderate or strong CYP3A and/or CYP2C19 inducers within 28 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
* Known participation in a clinical trial of PF-06651600 within 60 days prior to the first dose of investigational product; participation in any clinical trail of PF-06651600 and the participant experienced AE that led to discontinuation, or had SAE, that in the judgment of the investigator were PF-06651600-related.

Primary outcomes:
measure: Cmax (maximum plasma concentration) of PF-06651600
timeFrame: Hour 0, and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours post post Period 1, Day 1, Period 2, Day 8.
measure: AUC (Area under the curve) of PF-06651600
timeFrame: Hour 0, and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours post post Period 1, Day 1, Period 2, Day 8.
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Brussels Clinical Research Unit
state: Bruxelles-capitale, Région DE
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00649909: Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients
Official title: Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus, Type II
Keywords: Diabetes Mellitus
Type II
Aspirin
Resistance
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2008-04-01
Enrollment: 18
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Type 2 diabetic patients that take aspirin, from the diabetology clinic.

Brief summary: The efficacy of low dose aspirin appears to be substantially lower in diabetic patients, compared to patients without diabetes.

We will perform an observational study where we follow up patients with uncontrolled type 2 Diabetes Mellitus and low response to aspirin (Aspirin Resistance), during a period of 6 months in the diabetic clinic. Our hypothesis is that glucose control will improve the response to aspirin in those patients.


Eligibility criteria: Inclusion Criteria

1. Type 2 DM.
2. Patients that take aspirin.
3. Antecubital forearm veins allowing technically good sampling for platelet studies.
4. Reduced Laboratory response to aspirin.
5. HbA1c \> 8 %
6. The physician decides that there is an indication for glucose control.

Exclusion Criteria:

1. Acute ischemic stroke, acute coronary syndrome, (myocardial infarction or unstable angina pectoris), or revascularization by PCI or by-pass surgery within the last 6 months.
2. Acute kidney disease or chronic kidney disease with creatinine clearance \<30.
3. Acute liver disease or chronic liver disease with severe liver impairment.
4. Need for treatment with anticoagulants, clopidogrel, NSAID's, or thiazolidinediones.
5. Thrombocytopenia (platelet count \<150 x 109/L)

Primary outcomes:
measure: The outcome measure is the laboratory Aspirin Resistance.
timeFrame: 3 and 6 months.
Secondary outcomes:
measure: To determine the incidence of laboratory aspirin resistance in type 2 DM in stable out-patients in the diabetic clinic, and possibly related factors.
timeFrame: On screening visit.
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
affiliation: Hematology Department, Hadassah Medical Organization, Jerusalem, Israel
name: David Varon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02153385: Effects of Yoga on Heart Rate Variability and Mood in Women
Official title: Effects of Yoga on Heart Rate Variability and Mood in Women: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Rate Variability
Keywords: Yoga, heart rate variability, stress, mood, women
Lead sponsor: Kaohsiung Medical University
Sponsor class: OTHER
First posted: 2014-06-03
Enrollment: 52
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background: Women are more likely to suffer from depression and anxiety, which have been linked to reduced heart rate variability (HRV) and increased cardiovascular morbidity and mortality. The purpose of this study was to examine the effects of an 8-week yoga program on HRV and mood in generally healthy women. The investigators hypothesized that there would be improvements in HRV and reductions in perceived stress and symptoms of depression and anxiety after the yoga intervention.

Methods: Fifty-two healthy women were randomized to either a yoga group or a control group. Participants in the yoga group completed an 8-week yoga program, which comprised a 60-minute session, twice a week. Each session consisted of breathing exercises, yoga pose practice, and supine meditation/relaxation. Participants' HRV, perceived stress, depressive symptoms, and state and trait anxiety were assessed at baseline and week 9.


Eligibility criteria: Inclusion Criteria:

* women
* aged 18-50 years old
* body mass index \< 30 kg/m2

Exclusion Criteria:

* currently engaged in regular yoga practice
* pregnant
* nursing
* had physical contraindications to exercise

Primary outcomes:
measure: Change from baseline in heart rate variability at week 9
timeFrame: The ourcome measure was assessed at baseline and at week 9
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University
Study officials:
affiliation: Kaohsiung Medical University
name: I-Hua Chu, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05823285: A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
Official title: A Phase 1 Study to Investigate the Safety, Tolerability，Pharmacokinetics, Immunogenicity and Preliminary Effectiveness of QLS31903 Injection in Subjects With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Advanced Solid Tumors
Lead sponsor: Qilu Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-04-21
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate safety, pharmacokinetics,immunogenicity and efficacy of QLS31903 alone in the treatment of advanced cancer.


Eligibility criteria: Key Inclusion Criteria:

* 18 years or older, 40kg or heavier
* Histologically or cytologically confirmed diagnosis of advanced solid tumor （For phase 1b, patients must have solid tumor with GPC3+ )
* Standard treatment failed or standard treatment intolerant, no standard treatment
* Adequate hepatic, hematologic, and renal function

Key Exclusion Criteria:

* Anti-tumor treatment within 4 weeks prior to the first QLS31903 administration,except a few specific conditions
* Other clinical trial within 4 weeks prior to the first QLS31903 administration
* Receipt of a live or live attenuated vaccine within 30 days prior to the first QLS31903 administration
* Prior treatment targeted on GPC3
* HBsAg/HBcAb positive and HBV-DNA\>10,000 copy/mL;HCV-Ab positive and HCV-RNA\>1,000 copy/mL
* CNS metastasis (except asymptomatic brain metastases or symptomatic brain metastases after treatment stable for more than 4 weeks) and/or carcinomatous meningitis or leptomeningeal disease

Primary outcomes:
measure: Maximum tolerated dose（MTD）for Phase 1a
timeFrame: 21days or 14 days after the first target dose(whichever is longer）
measure: Recommended phase 2 dose(RP2D) for Phase 1a
timeFrame: Duration of study, approximately 24 months
measure: Objective Response Rate (ORR) for phase 1b
timeFrame: From fist administration of QLS31903 to disease progression，death，loss to follow up,withdrawal of consent,initiation of a new anticancer therapy,study completion/closure,whichever came first, assessed up to 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan Zhongshan Hospital
state: Shanghai
Study officials:
affiliation: Qilu Pharmaceutical Co., Ltd.
name: Xiaoyan Kang, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00002085: A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy
Official title: A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mycobacterium Avium-Intracellulare Infection
HIV Infections
Tuberculosis, Mycobacterium Infection
Keywords: Mycobacterium avium-intracellulare Infection
Acquired Immunodeficiency Syndrome
Azithromycin
Mycobacterium Infections, Atypical
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of azithromycin given chronically for the treatment of serious nontuberculous mycobacterial infection in patients failing or intolerant of other available therapy.


Eligibility criteria: Inclusion Criteria

Concurrent Medication:

Allowed:

* Other antimicrobial drugs as long as documented on Case Report Form.

Patients must have:

* Serious nontuberculous mycobacterial infection.
* Approval of eligibility from Pfizer Clinical Monitor. Patients below the legal age of consent must have consent of parent or guardian.

NOTE:

* Pregnant women, women of childbearing potential, and children will not be specifically excluded from participation. However, patients and physicians should be aware that the safety of azithromycin during pregnancy and in long-term use in children and adults has not been established. The risks and benefits of azithromycin use in these patients will be considered in consultation with the physician and the Pfizer Clinical Monitor.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Disseminated Mycobacterium avium complex (MAC) who are eligible for treatment with azithromycin under protocol 066-162.
* Known hypersensitivity or intolerance to macrolide antibiotics.

Patients with the following prior conditions are excluded:

History of hypersensitivity or intolerance to azithromycin.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Groton
country: United States
facility: Pfizer Central Research
state: Connecticut
city: Bethesda
country: United States
facility: Natl Cancer Institute / Metabolism Branch
state: Maryland
Study officials:
References: